The Role of Compounding Pharmacies
For much of the past decade, compounding pharmacies occupied a legal gray zone that allowed physicians to prescribe peptides not approved by the FDA — substances like CJC-1295, BPC-157, and sermorelin — as “compounded preparations” for individual patients. That landscape has changed materially in 2024–2025. Understanding what compounding pharmacies can and cannot do is essential for anyone evaluating a peptide therapy program through a clinic or physician.
The core principle: Compounding pharmacies prepare customized medications for specific patients with specific needs, where a commercially available product doesn’t exist or is medically inappropriate. Compounding is a legitimate, longstanding pharmacy practice — making a liquid suspension for a child who can’t swallow pills, for example, or removing a dye that a patient is allergic to from a standard formulation.
The peptide industry stretched this concept considerably.
503A vs 503B: The Two Types of Compounders
The FDA Drug Quality and Security Act (2013) created two distinct regulatory pathways for compounding pharmacies. These distinctions matter enormously for peptide access.
503A — Traditional Patient-Specific Compounding
503A pharmacies:
- Compound medications for individual patients with a valid prescription
- Operate under state pharmacy board oversight (not federal FDA inspection)
- Cannot make large batches without individual prescriptions
- May use bulk drug substances that appear on the FDA’s 503A Bulks List
- Cannot use bulk drug substances that the FDA has prohibited
This was the primary pathway through which most “peptide clinics” and telemedicine practices provided peptides. A physician would issue a prescription; a 503A pharmacy would compound the peptide.
503B — Outsourcing Facilities
503B outsourcing facilities:
- Registered with the FDA and subject to federal cGMP inspections (similar to pharmaceutical manufacturers)
- Can produce large batches without patient-specific prescriptions
- Supply to hospitals, clinics, and practitioners
- Subject to stricter quality controls and facility standards
- Can only use FDA-approved APIs or substances on the 503B Bulks List
- Increasingly the source for legitimate compounded semaglutide and tirzepatide (during shortage)
For peptides, 503B facilities are where FDA-cleared substances (like semaglutide during the shortage period) could be compounded at scale for clinical use.
The 2024–2025 FDA Enforcement Wave
What Changed
In October 2023, the FDA published a final rule placing several peptides on the 503A Prohibited Substances List — meaning 503A pharmacies could no longer compound them. The critical peptides affected:
| Peptide | Status | Effective |
|---|---|---|
| BPC-157 | Prohibited for 503A compounding | November 2023 |
| Sermorelin | Previously permitted under DESI, now restricted | Review ongoing |
| CJC-1295 | Prohibited for 503A compounding | November 2023 |
| Ipamorelin | Prohibited for 503A compounding | November 2023 |
| TB-500 (Thymosin β-4) | Prohibited for 503A compounding | November 2023 |
| Thymosin Alpha-1 | Prohibited for 503A compounding | November 2023 |
| PT-141 (Bremelanotide) | Permitted — FDA approved (Vyleesi) | N/A |
| Oxytocin | Ongoing review; some state restrictions | Variable |
Sermorelin occupies a unique position: it was previously marketed as Geref (withdrawn in 2008 for commercial, not safety, reasons). Its 503A status has been more contested, with some pharmacies still compounding under the DESI exemption; others have ceased. Regulatory attorneys differ on whether this remains permitted.
Why BPC-157 Was Specifically Targeted
The FDA’s reasoning for placing BPC-157 on the prohibited list centered on:
- No clinical trials in humans — the substance lacks Phase I safety data, let alone efficacy data
- No established safety standards — without clinical data, the FDA cannot set acceptable dosing or contamination limits
- Not a component of an approved drug — unlike peptides derived from approved molecules, BPC-157 has no approved reference product
The practical implication: any clinic or provider offering “compounded BPC-157” as an injectable after November 2023 is operating outside FDA regulations, regardless of what their marketing states.
What Can Still Be Legally Compounded
Semaglutide and Tirzepatide (GLP-1 Era)
The GLP-1 agonist shortage created an unusual situation: the FDA allowed both 503A and 503B facilities to compound semaglutide and tirzepatide during the shortage period (2022–2024). This created a large cottage industry.
Important update: As of early 2025, the FDA declared the semaglutide shortage resolved, beginning enforcement action against compounders. The situation for tirzepatide followed a similar path. By mid-2025:
- 503A pharmacies can compound semaglutide/tirzepatide only with documented patient-specific medical need (allergy, strength not commercially available, etc.)
- 503B facilities face similar restrictions as shortage justification dissolves
- Many compounders have ceased production; some continue under legal challenge
This is an actively evolving regulatory environment. Verify current status with your state pharmacy board.
Peptides Still Legally Accessible via Compounding
| Peptide | Pathway | Notes |
|---|---|---|
| Sermorelin | 503A (contested) | Verify with specific pharmacy |
| Oxytocin (Pitocin) | 503A with prescription | FDA approved reference product exists |
| PT-141 (Bremelanotide) | FDA approved (Vyleesi) | Compounding not typically needed; brand available |
| NAD+ | Not a peptide; 503A common | FDA has not prohibited; regulation ongoing |
How to Evaluate a Compounding Pharmacy
If you are working with a provider who prescribes compounded peptides, these factors distinguish reputable pharmacies from problematic ones:
1. PCAB or Comparable Accreditation
The Pharmacy Compounding Accreditation Board (PCAB) accredits pharmacies that meet enhanced quality standards. Not all reputable pharmacies have PCAB accreditation, but it is a positive signal.
2. State Licensure Verification
Every compounding pharmacy should be licensed in the state where it operates and in the state where the patient resides. The National Association of Boards of Pharmacy (NABP) maintains a verification database.
3. COA Access
Reputable compounders should be able to provide a Certificate of Analysis for the batch used to fill your prescription, including:
- Identity confirmation (mass spectrometry)
- Purity (HPLC)
- Sterility testing
- Endotoxin testing (for injectables)
- Potency/concentration
If a pharmacy cannot or will not provide this, that is a significant red flag.
4. Physician Oversight
Compounded prescriptions require a legitimate physician-patient relationship and a valid prescription. Telemedicine relationships where a “provider” auto-generates prescriptions for substances without a meaningful clinical evaluation do not constitute a legitimate patient-specific medical need.
5. What They’re Actually Compounding
After the 2023 prohibition, if a pharmacy is offering to compound BPC-157, CJC-1295, Ipamorelin, TB-500, or Thymosin Alpha-1 as injectables, they are violating federal regulations — regardless of what they tell you. This is a disqualifying finding.
The “Research Use Only” Alternative and Why It’s Different
Distinct from compounding pharmacies, a separate supply chain exists: research chemical suppliers who sell peptides labeled “for research use only, not for human use.” These are:
- Not pharmacies — they are chemical suppliers
- Not subject to pharmacy regulations — they operate under a different regulatory framework
- Not manufacturing to pharmaceutical standards — GMP does not apply
- Not filling prescriptions — the transaction is a commercial sale, not a dispensing
This is a separate (and separately risky) category. See the Sourcing & Safety Guide for a detailed breakdown of the research supply chain.
The Clinic Landscape Post-2023
Many peptide clinics have adapted their offerings following the 2023 FDA actions. Common adaptations include:
Legitimate pivots:
- Shifting focus to FDA-approved compounds (semaglutide, tirzepatide, PT-141)
- Emphasizing sermorelin (where legal)
- Offering lifestyle medicine and optimization services without prohibited compounds
Concerning patterns:
- Continuing to advertise BPC-157 and similar prohibited compounds as “available through our pharmacy partners”
- Pivoting language to describe compounds as “legal research peptides” administered “off-label”
- Shifting to “concierge” or “membership” models that add legal ambiguity
What this means for patients: If a clinic is still offering injectable BPC-157 or CJC-1295/Ipamorelin through a compounding pharmacy after late 2023, they are either uninformed about the regulatory change or are knowingly operating outside regulations. Neither is acceptable.
Working With a Legitimate Provider
The most defensible pathway for peptide therapy in 2025:
- Consult a physician who has reviewed your bloodwork and health history — not a telehealth questionnaire
- Ask specifically which peptides they’re prescribing and from which pharmacy
- Verify the pharmacy’s license through your state board
- Request the COA for the specific lot dispensed to you
- Understand the regulatory status of the specific compound — FDA approved, off-label compounded, or research-grade
- Ask the physician how they’re monitoring for effects and safety
Conclusion
Compounding pharmacies play a legitimate role in healthcare — but the peptide compounding landscape has been significantly reshaped by FDA enforcement. The prohibition of BPC-157, CJC-1295, Ipamorelin, TB-500, and Thymosin Alpha-1 from 503A compounding in late 2023 was a watershed moment. Many clinics have not communicated this clearly to patients.
Understanding what remains legally available — and what doesn’t — is a prerequisite for navigating this space safely.
For more on the research-grade supply chain and how to evaluate COAs, see the Sourcing & Safety Guide.